A cost-benefit analysis of the Quebec Network of Genetic Medicine.
Certain serious diseases, including several major genetic disorders, cannot be treated effectively unless they are detected before symptoms appear. In such cases, only systematic population screening can ensure that the necessary preventive treatment can be administered to affected individuals. The question of whether to establish such screening programs, which may be relatively costly, is a pressing problem for many public administrations. This study of the costs and benefits of the Quebec Network of Genetic Medicine has as its main objective the development of an analytical framework which can be generally applied to such problems. In this article, we attempt to evaluate the profitability of the Network to society. For the evaluation of the less tangible costs and benefits, we adopted the minimum profitability principle, which essentially involves establishing a lower bound on the value of the profitability of the Network. The net benefits assessed by this study, although certainly underestimated, are still very significant. Since the Network is administered by a team of researchers, the study also throws some light on the links existing between research and development activities on the one hand and public services on the other, and hence on the general question of the socioeconomic profitability of biomedical research.
D035843:Biomedical Research; D003362:Cost-Benefit Analysis; D005260:Female; D030342:Genetic Diseases, Inborn / Q000517:prevention & control*; D005821:Genetic Techniques / Q000191:economics*; D005820:Genetic Testing / Q000379:methods*; D006801:Humans; D007037:Hypothyroidism / Q000235:genetics; D007223:Infant; D007231:Infant, Newborn; D010661:Phenylketonurias / Q000517:prevention & control; D011247:Pregnancy; D011792:Quebec; D013661:Tay-Sachs Disease / Q000517:prevention & control; D014443:Tyrosine / Q000097:blood
D014443:Tyrosine